Epigenomics AG (ECX) - Product Pipeline Analysis, 2015 Update

Date: May 19, 2015
Pages: 35
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E30AEB3A78FEN
Leaflet:

Download PDF Leaflet

Epigenomics AG (ECX) - Product Pipeline Analysis, 2015 Update
Summary

Epigenomics AG (Epigenomics) is a molecular diagnostics company that develops and commercializes vitro diagnostic (IVD) tests for the screening, early detection and diagnosis of cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics' lead product: Epi proColon is a blood-based test for rapid detection of colorectal cancer. The company markets Epi proColon in Europe and it is under regulatory review by the FDA for the US. Epigenomics also offers Epi proLung BL Reflex assay for the diagnosis of lung cancer in Europe. Geographically, the company markets its products in Europe, North America and China. Epigenomics is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Epigenomics AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Epigenomics AG Company Snapshot
Epigenomics AG Company Overview
Key Information
Epigenomics AG Pipeline Products and Clinical Trials Overview
Epigenomics AG – Pipeline Analysis Overview
Business Description
Key Facts
Epigenomics AG - Major Products and Services
Epigenomics AG Pipeline Products by Development Stage
Epigenomics AG Clinical Trials by Trial Status
Epigenomics AG Pipeline Products Overview
Epi proColon
Epi proColon Product Overview
Epi proColon Clinical Trial
Epi proLung BL 1.0 - Blood Plasma
Epi proLung BL 1.0 - Blood Plasma Product Overview
Screening And Monitoring Test - Colorectal Cancer
Screening And Monitoring Test - Colorectal Cancer Product Overview
Screening And Monitoring Test - Lung Cancer
Screening And Monitoring Test - Lung Cancer Product Overview
Screening And Monitoring Test - Prostate Cancer
Screening And Monitoring Test - Prostate Cancer Product Overview
Septin9 Colorectal Cancer Test
Septin9 Colorectal Cancer Test Product Overview
Epigenomics AG - Key Competitors
Epigenomics AG - Key Employees
Epigenomics AG - Key Employee Biographies
Epigenomics AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Epigenomics AG, Recent Developments
May 12, 2015: Epigenomics Announces Q1 2015 Financial Results and Reports on Operational Highlights
May 08, 2015: Epigenomics Reaches 99.5 % Adherence for Epi proColon in ADMIT Study
Apr 28, 2015: Epigenomics receives EUR 2.8m grant for Validation of Lung Cancer Biomarkers in Blood Plasma
Mar 25, 2015: Epigenomics Reports Results for the Financial Year Ended December 31, 2014 and Provides Outlook for 2015
Mar 25, 2015: Epigenomics Announces Completion of Enrollment in Epi proColon ADMIT Trial
Dec 17, 2014: First Patients Enrolled in Epigenomics’ Epi proColon ADMIT Study
Dec 08, 2014: Epigenomics and BioChain Announce Approval of Epi proColon in China
Nov 11, 2014: Epigenomics Announces 2014 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights
Nov 03, 2014: Epigenomics strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon in the United States
Oct 27, 2014: Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon Improves Compliance to CRC Screening
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES
Epigenomics AG, Key Facts
Epigenomics AG Pipeline Products and Clinical Trials Overview
Epigenomics AG Pipeline Products by Equipment Type
Epigenomics AG Pipeline Products by Indication
Epigenomics AG Clinical Trials by Trial Status
Epigenomics AG, Key Facts
Epigenomics AG, Major Products and Services
Epigenomics AG Number of Pipeline Products by Development Stage
Epigenomics AG Pipeline Products Summary by Development Stage
Epigenomics AG Clinical Trials by Trial Status
Epigenomics AG Clinical Trials Summary
Epi proColon - Product Status
Epi proColon - Product Description
Epi proColon - Adherence to Minimally Invasive CRC Screening in Non-adherent Patients Who Have Not Completed Colorectal Cancer Screening
Epi proLung BL 1.0 - Blood Plasma - Product Status
Epi proLung BL 1.0 - Blood Plasma - Product Description
Screening And Monitoring Test - Colorectal Cancer - Product Status
Screening And Monitoring Test - Colorectal Cancer - Product Description
Screening And Monitoring Test - Lung Cancer - Product Status
Screening And Monitoring Test - Lung Cancer - Product Description
Screening And Monitoring Test - Prostate Cancer - Product Status
Screening And Monitoring Test - Prostate Cancer - Product Description
Septin9 Colorectal Cancer Test - Product Status
Septin9 Colorectal Cancer Test - Product Description
Epigenomics AG, Key Employees
Epigenomics AG, Key Employee Biographies
Epigenomics AG, Subsidiaries

LIST OF FIGURES
Epigenomics AG Pipeline Products by Equipment Type
Epigenomics AG Pipeline Products by Development Stage
Epigenomics AG Clinical Trials by Trial Status
Skip to top


Ask Your Question

Epigenomics AG (ECX) - Product Pipeline Analysis, 2015 Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: